ALEXION: Soliris’ Label Expansion & Diversification to Perk ALXN Up!
An another impressive quarter – robust sales in Paroxysmal Nocturnal Hemoglobinuria (PNH), steady uptake in atypical Hemolytic Uremic Syndrome (aHUS) indication, and label expansion in other rare and high unmet need indications of Soliris; we expect the growth trajectory continues in the long term. Positive PhII clinical data of Asfotase alfa (ENB-0040, PhII/III, hypophosphatasia, HPP) justifies the acquisition of Enobia and thus, ALXN’s diversification strategy. ALXN’s experience in developing and marketing orphan drugs should intact its value, despite any disappointments… For more details, please read our report released on April 25, 2012 on ALXN, titled “Soliris’ Label Expansion & Diversification to Perk ALXN Up!”
COMPANIES MENTIONED
ALEXION
ALEXION
More Publications
ALEXION - Geography + Label Expansion = Long Term Growth
US$ 140.00
July 2011
4 pages
ALEXION - Great Expectations From Label Expansion
US$ 140.00
September 2011
4 pages
Niche Products, Label expansion and No Competition - Growth Drivers
US$ 140.00
July 2011
7 pages
ALEXION: Orphan Drugs and Innovative Biologics = Irresistible Combination!
US$ 140.00
February 2012
6 pages
